Last updated on August 2018

Evaluation of Fiasp (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy


Brief description of study

This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp.

Detailed Study Description

This will be a randomized cross-over blinded study and to see how the 670G pump responds to the introduction of Fiasp insulin. Subjects enrolled in the study will have a 2 week period of optimization with weekly assessments of their Carelink download before entering the blinded phase of the study. They will use their usual home insulin during the optimization phase. They will then be started on their first blinded insulin (aspart or Fiasp) which they will use for 2 weeks, before they cross-over to the other insulin.

Clinical Study Identifier: NCT03554486

Find a site near you

Start Over

Stanford University

Palo Alto, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.